In order to provide the proprietary etrials EDC solution Cato Research has selected Merge Healthcare. This new agreement expands Merge’s partnership with CATO to provide additional technology for clinical trials management, as well as extending the relationship for an additional five years.
Allen Cato, M.D., Ph.D., and CEO of Cato Research Ltd. said, “We have enjoyed a long-standing partnership with Merge Healthcare for their clinical trial solutions. The etrials technology has been consistent and intuitive, and the Merge team has been quick to help us use it successfully. Adding the etrials EDC platform in a technology transfer model will enable our company to efficiently build and deliver solutions to help our customers run cost-effective clinical studies.”
The technology transfer program allows CATO to use the etrials EDC system to build and deploy custom clinical trial studies that leverage the powerful reporting capabilities of Merge’s technology. Because the etrials EDC solution is built on a SaaS platform, it can be licensed on a subscription or study basis. In addition, Merge’s etrials IVR and ePRO solutions can be integrated with the EDC system to provide comprehensive eClinical solutions. Merge’s team of clinical trial experts will also provide training and support to CATO.
Justin Dearborn, CEO of Merge said, “We are thrilled to partner with CATO to bring etrials EDC into their portfolio of clinical trial solutions. With our robust EDC offering, CATO will be able to deliver an easy-to-use solution to their clients. It is our goal to understand how our customers’ conduct business in order to deliver robust solutions that meet their long-term needs and allow for mutually beneficial partnerships like this one.”
Merge Healthcare develops and integrates information technology to create a better electronic healthcare experience. Merge products, ranging from standards-based development toolkits to sophisticated clinical applications, have been used by healthcare providers, vendors and researchers worldwide for over 20 years.
In the healthcare stories read here about how GlaxoSmithKline has decided to team up with well known public domain data providers, European Bioinformatics Institute, the U.S. National Library of Medicine and the U.S.-based informatics service provider Collaborative Drug Discovery. Their aim is to make available important scientific information of over 13,500 compounds that eventually contributes to the invention of new malaria treatments.
Hans Lewis is a contributing editor for HealthTechZone. To read more of his articles, please visit his columnist page.Edited by
Kelly McGuire
